- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hvivo strikes £11.5m RSV contract with existing client | 2 | Sharecast | ||
| Di | hVIVO PLC - £11.5m RSV contract and notice of trading update | - | RNS | ||
| 05.11. | hVIVO PLC - Presentation at Jefferies London Healthcare Conf | 1 | RNS | ||
| 11.10. | hVIVO PLC - Long Term Incentive Plan/ PDMR Notification | - | RNS | ||
| 07.10. | hVIVO upbeat on positive human challenge trial results with client | 1 | Sharecast | ||
| 07.10. | hVIVO PLC - Positive results from RSV human challenge trial | 1 | RNS | ||
| 30.09. | hVIVO gets HSE clearance, launches new lab services | 2 | Sharecast | ||
| 30.09. | hVIVO PLC - Launch of full suite of hLAB standalone services | - | RNS | ||
| HVIVO Aktie jetzt für 0€ handeln | |||||
| 10.09. | hVIVO hails "record" half-year revenue, as profit soars 70% higher | 2 | Alliance News | ||
| 10.09. | Clinical trial specialist hVivo's H1 revenues jump by 30% | 1 | RTE.ie | ||
| 10.09. | hVIVO PLC - Interim results | 1 | RNS | ||
| 20.08. | hVIVO PLC - Notice of results | 2 | RNS | ||
| 05.08. | JD Wetherspoon chair offloads 1% stake while hVIVO chair exits the register | Directors Deals | 1 | Shares | ||
| 05.08. | Life sciences firm hVIVO cancels Euronext listing to focus on London | 1 | City A.M. | ||
| 05.08. | Three Quick Facts: UK Oil & Gas, Clarkson, hVIVO | 1 | The Armchair Trader | ||
| 05.08. | hVIVO PLC - Euronext cancellation | - | RNS | ||
| 23.07. | hVIVO PLC - Director/PDMR Shareholding | - | RNS | ||
| 17.07. | hVivo expects half year revenues to rise by 30% | 1 | RTE.ie | ||
| 17.07. | hVIVO reports 31% revenue jump; relocation to improve efficiencies | 1 | Alliance News | ||
| 17.07. | Hvivo delivers record revenues in H1, reiterates FY guidance | 1 | Sharecast |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 1,250 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium | ||
| SPINEWAY | 0,084 | 0,00 % | Spineway provides an update on its activities during a webinar - Arrival of a new CFO | Press release Ecully, December 6, 2024 - 6 p.m. Spineway provides an update on its activities during a webinarArrival of a new CFO The Spineway Group, a specialist in innovative implants for... ► Artikel lesen | |
| ASENSUS SURGICAL | 0,305 | 0,00 % | KARL STORZ akquiriert den US-amerikanischen Robotik-Spezialisten Asensus Surgical | Tuttlingen / Research Triangle Park, USA (ots) - Das familiengeführte und international agierende Medizintechnikunternehmen KARL STORZ gibt die Akquisition des innovativen Robotik-Spezialisten Asensus... ► Artikel lesen | |
| MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve president, CEO Preiner resigns | ||
| LIFEWARD | 1,890 | 0,00 % | Lifeward Ltd. Reports Third Quarter 2024 Financial Results | Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors ... ► Artikel lesen | |
| JD HEALTH | 3,660 | -1,61 % | JD Health-Aktie verliert 2,56 Prozent (3,43 €) | Im Minus liegt aktuell das Wertpapier von JD Health . Der jüngste Kurs betrug 3,43 Euro. Heute hat sich an der Börse die JD Health-Aktie zwischenzeitlich um 2,56 Prozent verbilligt. Der Kurs des Wertpapiers... ► Artikel lesen | |
| EKSO BIONICS | 0,690 | +6,15 % | Ekso Bionics-Aktie stürzt auf 52-Wochen-Tief von 0,65 US-Dollar | ||
| IMUNON | 0,800 | -5,33 % | Imunon, Inc.: IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 | Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian... ► Artikel lesen | |
| ROCKWELL MEDICAL | 2,010 | +1,98 % | Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter | WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis... ► Artikel lesen | |
| AVINGER | 0,830 | +0,16 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| VIRIDIAN THERAPEUTICS | 18,000 | -0,55 % | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| SINTX TECHNOLOGIES | 3,350 | -14,32 % | SINTX Technologies, Inc.: SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 | Salt Lake City, UT, Nov. 14, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components... ► Artikel lesen | |
| AETHLON MEDICAL | 0,350 | -2,23 % | Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update | Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid... ► Artikel lesen | |
| STAGEZERO LIFE SCIENCES | 0,028 | -100,00 % | StageZero Life Sciences Ltd: StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order | TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene... ► Artikel lesen | |
| NEURONETICS | 1,048 | -1,50 % | Neuronetics, Inc. - 8-K, Current Report |
Das Unternehmen HVIVO PLC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,85 % bei einem Aktienkurs von 0,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.
